Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Elif Dereli Eke"'
Autor:
Simona Bernardi, Michele Malagola, Camilla Zanaglio, Nicola Polverelli, Elif Dereli Eke, Mariella D’Adda, Mirko Farina, Cristina Bucelli, Luigi Scaffidi, Eleonora Toffoletti, Clara Deambrogi, Fabio Stagno, Micaela Bergamaschi, Luca Franceschini, Elisabetta Abruzzese, Maria Domenica Divona, Marco Gobbi, Francesco Di Raimondo, Gianluca Gaidano, Mario Tiribelli, Massimiliano Bonifacio, Chiara Cattaneo, Alessandra Iurlo, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by
Externí odkaz:
https://doaj.org/article/e6d3474f9f274cd68adcb4e933b79eb1
Publikováno v:
Cell Communication and Signaling, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background Rapamycin is a potent inhibitor of the highly conserved TOR kinase, the nutrient-sensitive controller of growth and aging. It has been utilised as a chemotherapeutic agent due to its anti-proliferative properties and as an immunos
Externí odkaz:
https://doaj.org/article/d75d0b858d094eeba00e35b8f7b4f96a
Autor:
M. Malagola, N. Polverelli, V. Cancelli, E. Morello, A. Turra, E. Borlenghi, F. Cattina, B. Rambaldi, S. Bernardi, C. Zanaglio, Elif Dereli Eke, L. Gandolfi, M. Farina, D. Russo
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (E
Externí odkaz:
https://doaj.org/article/382c0d489cd9414f8b51a0a43665bb6c
Autor:
Mario Tiribelli, Chiara Cattaneo, Massimiliano Bonifacio, Fabio Stagno, Cristina Bucelli, Luigi Scaffidi, Gianluca Gaidano, Mariella D'Adda, Mirko Farina, Domenico Russo, Eleonora Toffoletti, Elif Dereli Eke, Clara Deambrogi, Simona Bernardi, Francesco Di Raimondo, Michele Malagola, Marco Gobbi, Alessandra Iurlo, Luca Franceschini, Maria Domenica Divona, Nicola Polverelli, Camilla Zanaglio, Micaela Bergamaschi, Elisabetta Abruzzese
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Cancer Medicine, Vol 8, Iss 5, Pp 2041-2055 (2019)
Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1094e370f7f142d005fac333aed01e8d
https://doi.org/10.1002/cam4.2087
https://doi.org/10.1002/cam4.2087
Autor:
Mirko Farina, Benedetta Rambaldi, Simona Bernardi, Lisa Gandolfi, Enrico Morello, Michele Malagola, Alessandro Turra, Federica Cattina, Valeria Cancelli, Elif Dereli Eke, Nicola Polverelli, Erika Borlenghi, Camilla Zanaglio, Domenico Russo
Publikováno v:
Case Reports in Hematology
Case Reports in Hematology, Vol 2019 (2019)
Case Reports in Hematology, Vol 2019 (2019)
We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b83f2c4565411bfb85bcd97276efa89
http://europepmc.org/articles/PMC6594262
http://europepmc.org/articles/PMC6594262
Autor:
Emir Erkol, Betul Kirdar, Duygu Dikicioglu, Arzu Celik, Barbara Di Camillo, Elif Dereli Eke, Kazim Yalcin Arga, Serpil Eraslan
Target of rapamycin (TOR) is a major signaling pathway and regulator of cell growth. TOR serves as a hub of many signaling routes, and is implicated in the pathophysiology of numerous human diseases, including cancer, diabetes, and neurodegeneration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::703d8e76c9c8f17a10a4e3fa32ba9b3a
Publikováno v:
Cell Communication and Signaling
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 16, Iss 1, Pp 1-13 (2018)
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 16, Iss 1, Pp 1-13 (2018)
Background: Rapamycin is a potent inhibitor of the highly conserved TOR kinase, the nutrient-sensitive controller of growth and aging. It has been utilised as a chemotherapeutic agent due to its anti-proliferative properties and as an immunosuppressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22845183ff968b59e2ca5ddc83fd5f3a
http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8161
http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8161
Autor:
Luca Franceschini, Massimiliano Bonifacio, Francesco Di Raimondo, Fabio Stagno, Simona Bernardi, Giuseppe Rossi, Camilla Zanaglio, Nicola Polverelli, Elisa Cerqui, Mirko Farina, Cristina Bucelli, Mario Tiribelli, Eleonora Toffoletti, Malgorzata Monika Trawinska, Marco Gobbi, Alessandra Iurlo, Michele Malagola, Gianluca Gaidano, Mariella D'Adda, Domenico Russo, Stefania Stella, Maria Teresa Voso, Micaela Bergamaschi, Clara Deambrogi, Elisabetta Abruzzese, Doriana Gramegna, Elif Dereli Eke, Paolo Vigneri
Publikováno v:
Blood. 132:3012-3012
Current therapy of CML with tyrosine kinase inhibitors (TKIs) aims to achieve a Major Molecular Response to avoid the disease progression to blastic phase and, possibly, a Deep Molecular Response (DMR), to gain the opportunity for TKIs discontinuatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65b9d5820b06eec312a7175efc6a30e7
https://doi.org/10.1182/blood-2018-99-112391
https://doi.org/10.1182/blood-2018-99-112391
Autor:
Nicola Polverelli, Stefania Masneri, Mirko Farina, Federica Cattina, Domenico Russo, Simona Bernardi, Francesca Schieppati, Alessandro Turra, Benedetta Rambaldi, Camilla Zanaglio, Enrico Morello, Michele Malagola, Elif Dereli Eke
Publikováno v:
Blood. 132:4387-4387
Introduction In AML and MDS cases, the genetic lesions inherited or acquired by the hematopoietic stem cells are considered as starting events. Familial AML and MDS, recently recognized in the revised WHO classification (2016) provide a useful model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79b3eb350a184b66dafa62fbb6936e50
https://doi.org/10.1182/blood-2018-99-109927
https://doi.org/10.1182/blood-2018-99-109927